Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia

Japanese Journal of Clinical Oncology

Volumn 41, Issue 8, 2011, Pages 964-972

  Ikeda, Eiji ^a   Kojima, Takashi ^a   Kaneko, Kazuhiro ^a   Minashi, Keiko ^a   Onozawa, Masakatsu ^a   Nihei, Keiji ^a   Fuse, Nozomu ^a   Yano, Tomonori ^a   Yoshino, Takayuki ^a   Tahara, Makoto ^a   Doi, Toshihiko ^a   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Dysphagia; Esophageal cancer; Palliative chemoradiotherapy; Squamous cell carcinoma; Stage IVB

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; DISEASE SEVERITY; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ESOPHAGUS CANCER; ESOPHAGUS PERFORATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERKALEMIA; HYPONATREMIA; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RASH; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DEGLUTITION DISORDERS; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; HYPONATREMIA; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; NUTRITIONAL SUPPORT; PALLIATIVE CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79961043421     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr088     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2009 Foundation for Promotion of Cancer Research.
3. The Japanese Society for Esophageal Diseases. Comprehensive Registry of Esophageal Cancer in Japan (1998, 1999) and Long-term Results of Esophagectomy in Japan (1988-1997). 3rd edn. 2002.
4. Javle M, Ailawadhi S, Yang GY, Nwogu CE, Schiff MD, Nava HR. Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol 2006;4:365-73, 79.
5. Lam YH, Chan A, Lau J, Lee D, Ng E, Wong S, et al. Self-expandable metal stents for malignant dysphagia. Aust N Z J Surg 1999;69:668-71.
6. Ludwig D, Dehne A, Burmester E, Wiedemann GJ, Stange EF. Treatment of unresectable carcinoma of the esophagus or the gastroesophageal junction by mesh stents with or without radiochemotherapy. Int J Oncol 1998;13:583-8.
7. Wong SK, Chiu PW, Leung SF, Cheung KY, Chan AC, Au-Yeung AC, et al. Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study. Ann Surg Oncol 2008;15:576-82.
8. Berger B, Belka C. Evidence-based radiation oncology: oesophagus. Radiother Oncol 2009;92:276-90.
9. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol 1999;26(5 Suppl 15):12-20.
10. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001;31:419-23.
11. Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002;86:669-73.
12. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-20.
13. Iizuka T, Kakegawa T, Ida H, Ando N, Watanabe H, Takagi I. Phase II evaluation of combined cisplatin and vindesine in advanced squamous cell carcinoma of the esophagus: Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1991;21:176-9.
14. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992;22:172-6.
15. Homs MY, v d Gaast A, Siersema PD, Steyerberg EW, Kuipers EJ. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev 2006:CD004063.
16. Levard H, Pouliquen X, Hay JM, Fingerhut A, Langlois-Zantain O, Huguier M, et al. 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg 1998;164:849-57.
17. Harvey JA, Bessell JR, Beller E, Thomas J, Gotley DC, Burmeister BH, et al. Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Dis Esophagus 2004;17:260-5.
18. Hayter CR, Huff-Winters C, Paszat L, Youssef YM, Shelley WE, Schulze K. A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer. Radiother Oncol 2000;56:329-33.
19. Burmeister BH, Denham JW, O'Brien M, Jamieson GG, Gill PG, Devitt P, et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys 1995;32:997-1006.
20. Burmeister BH, Walpole ET, Burmeister EA, Thomas J, Thomson DB, Harvey JA, et al. Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin. Int J Clin Oncol 2005;10:256-61.
21. Cho SH, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, et al. Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus 2008;21:697-703.
22. Coia LR, Soffen EM, Schultheiss TE, Martin EE, Hanks GE. Swallowing function in patients with esophageal cancer treated with concurrent radiation and chemotherapy. Cancer 1993;71:281-6.
23. Urba SG, Turrisi AT, 3rd. Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus. Cancer 1995;75:435-9.
24. Bown SG, Hawes R, Matthewson K, Swain CP, Barr H, Boulos PB, et al. Endoscopic laser palliation for advanced malignant dysphagia. Gut 1987;28:799-807.
25. O'Rourke IC, Tiver K, Bull C, Gebski V, Langlands AO. Swallowing performance after radiation therapy for carcinoma of the esophagus. Cancer 1988;61:2022-6.
26. Diseases JSfE. Guidelines for the Clinical and Pathological Studies on Carcinoma of the Esophagus (in Japanese). 9th edn. Tokyo: Kanehara Shuppan 1999:59-79.
27. Takubo K, Makuuchi H, Fujita H, Aikou T, Kajiyama Y, Kawano T, et al. Japanese Classification of Esophageal Cancer, tenth edition: part 1. Esophagus 2009;6:1-25.
28. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999;17:2915-21.
29. Iwase H, Shimada M, Nakamura M, Nakarai K, Iyo T, Kaida S, et al. Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy. Int J Clin Oncol 2003;8:305-11.
30. Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 2003;88:18-24.
31. Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 2002;53:134-9.
32. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8.
33. Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005;35:316-23.
34. Tanaka T, Fujita H, Matono S, Nagano T, Nishimura K, Murata K, et al. Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org). Dis Esophagus 2010;23:646-51.
35. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
36. Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. Jpn J Clin Oncol 2008;38:464-8.